CTI BioPharma
223 articles about CTI BioPharma
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 29, 2021
11/29/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to nine new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 09, 2021
11/9/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Presentations at the 63rd American Society of Hematology Meeting
11/4/2021
CTI BioPharma Corp. (Nasdaq: CTIC) today announced five poster presentations from the Company's pacritinib program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia , December 11-14, 2021 .
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 14, 2021
10/14/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 28, 2021
9/28/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to fourteen new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 17, 2021
9/17/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to twenty-five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 26, 2021
8/26/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction
8/25/2021
CTI BioPharma Corp. today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA).
-
CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors
8/24/2021
CTI BioPharma Corp. announced the appointment of Diane Parks to its Board of Directors.
-
CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021
7/29/2021
CTI BioPharma Corp. announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 26, 2021
7/26/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 09, 2021
7/9/2021
CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 23, 2021
6/23/2021
CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 09, 2021
6/9/2021
CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16
6/9/2021
CTI BioPharma Corp. announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET.
-
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis
6/1/2021
CTI BioPharma Corp. announced that the U.S. Food and Drug Administration has accepted its New Drug Application for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, with the NDA being granted Priority Review.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 26, 2021
5/26/2021
CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to six new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 13, 2021
5/13/2021
CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company.
-
CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021
5/5/2021
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021 , after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results